×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MAZE – maze therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MAZE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
12:27 pm
maze
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
Low
Report
Maze Therapeutics (MAZE) had its price target raised by JPMorgan Chase & Co. from $52.00 to $58.00. They now have an "overweight" rating on the stock.
3/28
01:05 am
maze
Maze Therapeutics (MAZE) was upgraded by Wall Street Zen from "sell"
Medium
Report
Maze Therapeutics (MAZE) was upgraded by Wall Street Zen from "sell"
3/26
09:40 am
maze
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/25
01:51 pm
maze
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
3/25
11:17 am
maze
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
Medium
Report
Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.
3/25
07:00 am
maze
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
High
Report
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
3/25
07:00 am
maze
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
High
Report
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
3/21
10:40 pm
maze
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
Low
Report
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
04:08 pm
maze
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bachrodt Amy
Low
Report
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bachrodt Amy
4/2
04:08 pm
maze
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bernstein Harold
Low
Report
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bernstein Harold
4/1
04:13 pm
maze
Form 4 Maze Therapeutics, Inc. For: Mar 30 Filed by: Dandekar Atul
Low
Report
Form 4 Maze Therapeutics, Inc. For: Mar 30 Filed by: Dandekar Atul
4/1
04:01 pm
maze
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Paradigm Biocapital Advisors LP
3/31
04:14 pm
maze
Form 4 Maze Therapeutics, Inc. For: Mar 27 Filed by: Kumar Neil
Low
Report
Form 4 Maze Therapeutics, Inc. For: Mar 27 Filed by: Kumar Neil
3/31
04:12 pm
maze
Form 3 Maze Therapeutics, Inc. For: Mar 27 Filed by: Kumar Neil
Low
Report
Form 3 Maze Therapeutics, Inc. For: Mar 27 Filed by: Kumar Neil
3/30
05:34 pm
maze
Form 144 Maze Therapeutics, Inc. Filed by: Dandekar Atul
Low
Report
Form 144 Maze Therapeutics, Inc. Filed by: Dandekar Atul
3/25
07:12 am
maze
Form 10-K Maze Therapeutics, Inc. For: Dec 31
High
Report
Form 10-K Maze Therapeutics, Inc. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: